IP Library Granted Patent US 7,807,174
Granted Patent B2
US 7,807,174 · App. 10/939,262 · Granted Oct 5, 2010

Class of therapeutic protein based molecules

Assignees: NexBio, Inc.; The United States of America/NIH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,807,174
App. No.
10/939,262
Granted
Oct 5, 2010
Kind
B2
Abstract

The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.

Claims (20)

1. A fusion protein comprising:

at least one catalytic domain of a sialidase, wherein the catalytic domain of the sialidase comprises the sequence of amino acids extending from amino acid 274 to amino acid 667 of SEQ ID NO:12, inclusive and lacks the sequence that consists of the sequence extending from amino acid 1 to amino acid 273 and from amino acid 668 to amino acid 901 of SEQ ID NO:12; and

at least one anchoring domain, wherein the anchoring domain is a glycosaminoglycan (GAG) binding domain of human amphiregulin comprising the amino acid sequence of SEQ ID NO:7.

2. The fusion protein of claim 1 , wherein the fusion protein comprises the sequence of amino acids set forth in SEQ ID NO:19.

3. The fusion protein of claim 1 , wherein the fusion protein comprises the sequence of amino acids set forth in SEQ ID NO:37.

4. A fusion protein comprising:

at least one catalytic domain of a sialidase, wherein the catalytic domain of the sialidase comprises the sequence of amino acids extending from amino acid 274 to amino acid 666 of SEQ ID NO:12 and lacks the sequence that consists of the sequence extending from amino acid 1 to amino acid 273 and from amino acid 667 to amino acid 901 of SEQ ID NO:12; and

at least one anchoring domain, wherein the anchoring domain is a glycosaminoglycan (GAG) binding domain of human amphiregulin comprising the amino acid sequence of SEQ ID NO:7.

5. The fusion protein of claim 4 , wherein the fusion protein comprises the sequence of amino acids set forth in SEQ ID NO:21.

6. A pharmaceutical formulation comprising the fusion protein of claim 5 .

7. A method of treating or preventing viral infection by influenza or parainfluenza, comprising: applying a therapeutically effective amount of the formulation of claim 6 to epithelial cells of a subject.

8. A fusion protein, wherein the fusion protein consists of the sequence of amino acids set forth in SEQ ID NO:21.

9. A pharmaceutical formulation comprising the fusion protein of claim 8 .

10. A method of treating or preventing viral infection by influenza or parainfluenza, comprising: applying a therapeutically effective amount of the formulation of claim 9 to epithelial cells of a subject.

11. A pharmaceutical formulation comprising the fusion protein of claim 1 .

12. The pharmaceutical formulation of claim 6 that is formulated as a spray, an inhalant, a solution for injection, a solution for eye drops, a cream, a salve, a gel, an ointment, a pill, a tablet, a lozenge, a suspension, or a solution that can be administered orally.

13. The pharmaceutical formulation of claim 11 that is formulated as a spray, an inhalant, a solution for injection, a solution for eye drops, a cream, a salve, a gel, an ointment, a pill, a tablet, a lozenge, a suspension, or a solution that can be administered orally.

14. A method of treating or preventing viral infection by influenza or parainfluenza, comprising: applying a therapeutically effective amount of the formulation of claim 11 to epithelial cells of a subject.

15. The method of claim 10 , wherein the applying is by nasal spray or by inhaler.

16. The method of claim 14 , wherein the applying is by nasal spray or by inhaler.

Assignments (4)
CHANGE OF NAME Recorded Jul 11, 2019
From: NEXBIO, INCORPORATED
To: ANSUN BIOPHARMA, INC.
Reel/Frame 049745/0694 →
CONFIRMATORY LICENSE Recorded Mar 26, 2010
From: NEXBIO, INC.
To: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTE OF HEALTH
Reel/Frame 024143/0832 →
CONFIRMATORY LICENSE Recorded Mar 25, 2010
From: NEXBIO, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024135/0391 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2008
From: FANG, FANG; MALAKHOV, MICHAEL
To: NEXBIO, INC.
Reel/Frame 020669/0036 →
Continuity (3)
Provisional Application 6056174900 · Apr 13, 2004
Provisional Application 6058008400 · Jun 16, 2004
Related Publication 20050112751A1 · May 26, 2005